Abstract
Human leukocyte antigen (HLA)-G is an immunomodulatory molecule discovered for the first time in the maternal–fetal interface. In cancer context, where high number of natural killer (NK) cells is described, the presence of HLA-G in its soluble form is thought to be essential for NK cells signaling. To evaluate intracellular signaling in NK cells upon HLA-G soluble forms stimulation, we investigate the role of soluble HLA-G (HLA-G5- and HLA-G1 shedding form) stimulation on classical nuclear factor (NF)–κB pathway activation. We reported that these two forms of soluble HLA-G could activate NF–κB in NK cells. NF–κB activation in NK cells does implicate neither phosphatidylinositol 3-kinase (PI3K) nor MEK (MAP kinase kinase) as demonstrated after specific inhibition experiments. We demonstrated elsewhere that NF–κB activation in NK cells is not implicated in cytotoxicity inhibition by HLA-G. Our findings may suggest the important role played by NF–κB activation after soluble HLA-G stimulation in other NK cells function.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
HLA-G is a non-classical human leukocyte antigen (HLA) class I antigen playing an important role in immune tolerance [1]. For instance, HLA-G molecule could inhibit cytotoxicity of natural killer (NK) [20, 27, 29] and CD8+ T cells [15]. In addition, it could inhibit alloproliferation of T cells in mixed lymphocyte reaction [17, 18] and polarize cytokine secretion to the Th2 profile [11, 12]. Many studies have greatly advanced in the knowledge about HLA-G functions in immune responses regulation, thus underlining its crucial role in understanding pathologies. The expression of HLA-G molecule by grafts avoids their rejection [28]. By contrast, the expression of HLA-G molecule by tumoral cells allows their escape from immune system [30].
After alternative splicing of the HLA-G primary transcript, seven isoforms are, at least, produced. Four are membrane-bound forms (HLA-G1, HLA-G2, HLA-G3, and HLA-G4), and three are soluble forms (HLA-G5, HLA-G6, and HLA-G7). In addition, a shedding form of HLA-G1 was described. This later is produced by metalloproteinases proteolytic cleavage at the cellular membrane. The cleavage site is situated at ten or 20 amino acids apart from the distal of α3 domain. The produced shedding HLA-G1 form is smaller than HLA-G5 by about 1–2 kDa [22].
HLA-G receptors are divided into specific receptors (killer immunoglobulin-like receptor, KIR2DL4) and non-specific [immunoglobulin-like transcript receptor (ILT)-2, ILT-4] inhibitory receptors [3, 39]. However, questions remain regarding the signaling pathways driven by HLA-G in immune cells. In a single and recently published study, we demonstrated that HLA-G activates the classical NF–кB pathway, with subsequent production of IкB-α subunit after accumulation of NF–кB in the nucleus. We showed that a membrane form of HLA-G (HLA-G1) rapidly activates NF–кB in NK cells. Interestingly, we demonstrated that this activation occurs through the alpha1 domain of HLA-G1. Finally, we hypothesized that NF–кB activation may result from a direct interaction of HLA-G1 with KIR2DL4 receptor [9].
NF–кB is a ubiquitous heterodimeric transcription factor implicated in pro-inflammatory responses, auto-immune diseases, and cancer. The most known complex is constituted from p50 and p65 (relA) subunits. In its inactive form, NF–κB is associated to the inhibitory protein IкB-α. After activation of NF–кB, IкB-α will be degraded by the 26S proteasome, thus releasing the dimers and allowing their translocation to the nucleus.
Since the presence of high levels of HLA-G soluble forms in the serum of patients with melanoma [36] or lymphoproliferative disorders [31] and of high number of NK cells in tumor tissues associated to NF–кB constitutive activation in numerous tumors [14], we investigated in this present work the classical NF–кB signaling pathway activation mediated by soluble HLA-G in NK cells. We focused on the role of two soluble forms of HLA-G: HLA-G5 and the shedding form of HLA-G1, in NF–кB activation in NK cells, which has not been addressed yet. In addition, we investigated whether NF–кB activation by HLA-G could implicate PI3K/protein kinase B (Akt) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathways. We focused also on the implication of NF–κB activation in NK cells cytotoxicity inhibition by HLA-G.
Materials and methods
Antibodies and reagents
For immunoblotting, we used specific antibodies raised against IкB–к anti–IкB-α (Santa Cruz, CA, USA) against the phosphorylated form of IкB-α (Ser32/Ser36, anti-pIкB-α Cell Signalling Technology, Danvers, USA) and against tubulin (Sigma, Saint-Quentin Fallavier, France). Recombinant human TNF-α purchased from Santa Cruz Biotechnology was dissolved in sterilized water. phosphatidylinositol 3-kinase (PI3K) inhibitor LY-294.002 and MAP kinase kinase (MEK) inhibitor PD-98.059, purchased from Sigma, were dissolved, respectively, in ethanol and dimethyl sulfoxide (DMSO). The synthetic peptide corresponding to the alpha-1 domain of HLA-G was produced by Jerini (Berlin, Germany) and dissolved in 10% acetonitrile.
Cell culture and treatments
M8 melanoma cells transfected with HLA-G1cDNA (M8-HLA-G1) or with empty vector pcDNA3.1/hygro(−) (M8-pcDNA) as previously described [23] were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 2 mM l-glutamine, and 100 µg/ml hygromycin B. Two NK cell lines were used: the NKL and YT2C2-PR. NKL cell line (kindly provided by E.H. Weiss, Munich, Germany) was cultured in RPMI 1640 medium with 10% FCS, 2 mM l-glutamine, and 50 U/ml IL-2 (Sigma-Aldrich). NK-like YT2C2-PR cell line was maintained in RPMI medium supplemented with 10% FCS and 2 mM l-glutamine. All maintenance media contained 10 µg/ml gentamicin and 0.25 µg/ml fungizone (Invitrogen). NKL cells express both ILT2 and KIR2DL4 receptors whereas YT2C2-PR cells express only KIR2DL4 as previously described [4, 9, 26]. For co-culture experiments, we incubated non-adherent NK cells, as previously described [9], on a layer of M8-pcDNA or M8-HLA-G1 adherent cells. PI3K inhibitor LY-294.002 and MEK inhibitor PD-98.059 were used at 50 and 30 µM, respectively, as previously described [5, 8].
Preparation of shedding HLA-G1 and HLA-G5 beads
HLA-G1 shedding form was produced in the supernatant of M8-HLA-G1 cells treated with TNF-α at 50 ng/ml for 12 h as previously described [40]. Recombinant HLA-G5 protein was produced in SF9 insect cells transfected with both HLA-G5 baculovirus and human beta2-microglobulin (Appligene-Oncor, Illkirch, France). After purification of HLA-G5 protein from SF9 supernatant, it was captured onto magnetic microbeads (diameter 300 nm, Ademtech, Pessac, France). HLA-G5-coated beads were used as a source of HLA-G5 at 4 × 103 beads/cell.
Immunoblot analysis
The immunoblotting procedure used in the present study has already been described in our previous study [40]. Briefly, after cell stimulations proteins were extracted in a buffer containing 50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 10% glycerol, 1% Nonidet P-40, and complete protease inhibitor (Roche, Basel, Switzerland) and quantified by the micro-BCA assay (Pierce, Rockford, USA). Protein extracts were mixed with an equal volume of Laemmli's buffer with 10% dithiothreitol followed by heating for 5 min at 95°C. Proteins were loaded on SDS–polyacrylamide gel, subjected to electrophoresis and finally transferred onto nitrocellulose membrane. Blots were either incubated with anti-IкB-α or with anti-pIкB-α. For the detection of the primary antibody, blots were incubated with the appropriate horseradish peroxidase-conjugated antibodies and treated with enhanced chemiluminescent substrate (SuperSignal West Pico, Pierce). Intensities of signals were analyzed using scanning densitometry AlphaEaseFC Software (Fluorchem 8800 imaging). Probed membranes with anti-IкB-α or with anti-pIкB-α were stripped of bound antibodies and reprobed with anti-tubulin used for normalization of densitometric measurements.
Cytotoxicity assay
The implication of NF–кB activation in the decreased cytotoxicity after HLA-G stimulation was determined by cytotoxicity assay that measure 51Cr released from target cells (M8-pcDNA cells versus M8-HLA-G1). NKL effector cells were previously stimulated overnight with IL-2 (100 U/ml, Sigma) at 37°C. M8-pcDNA or M8-HLA-GI target cells previously labeled for 1 h with 100 µCi 51Cr were incubated for 4 h at 37°C with NKL cells. Supernatants (50 µl) were harvested for scintillation counting by Wallac 1450 Microbeta (EGG instruments, Every, France). The experiment was reproduced four times in triplicate. We calculated the percentage of specific lysis as previously described. Briefly, percentage of specific lysis equals \( \left[ {\left( {{\hbox{experimental release}}--{\hbox{spontaneous release}}} \right)/\left( {{\hbox{maximum release}}--{\hbox{spontaneous release}}} \right)} \right] \times 100 \). Blockage experiments of NF–кB with a specific inhibitor: BAY 11-7082 (BAY, Calbiochem, Darmstadt, Germany) [24] were carried out by stimulation of NKL cells with 5 µM of BAY for 1 h at 37°C under 5% CO2 before cytotoxic assay.
Statistical analysis
Statistical differences between means in each experiment were performed using Student's t test and ANOVA test. The difference was considered statistically significant when p < 0.05 with 95% confidence interval.
Results
Soluble HLA-G5 activates NF–кB in NK Cells
HLA-G5 is the most important soluble form of HLA-G. It is implicated in various functions of HLA-G either in vitro or in vivo [16, 20]. NF–кB activation by soluble HLA-G5 stimulation was determined by Western blotting using anti-phospho-IкB-α. NKL cells (5 × 105 cells/ml) were treated by HLA-G5-coated beads (at 4 × 103 beads/cell) at three different times: 10, 15, and 20 min. We observed, as shown in Fig. 1, that soluble HLA-G5 phosphorylates the IкB-α subunit, in a time-dependent manner with a maximum at 15 min. Densitometric measurements show statistical significance of IкB-α phosphorylation which reveals the activation of NF–кB pathway in NKL cell line by soluble HLA-G5.
Shedding HLA-G1 activates NF–кB in NK cells
It was reported that the proteolytic cleavage of HLA-G1 by metalloproteinases produced another HLA-G soluble form commonly known as HLA-G1 shedding [22] which is thought to be abundant in cancer context [2]. To assess whether this soluble form (HLA-G1 shedding) was capable to activate the classical NF–κB pathway, we performed experiments providing NF–кB pathway activation through the IкB-α subunit cleavage.
NKL cells (5 × 105 cells/ml) were treated with supernatants isolated from M8-HLA-G1 cells previously stimulated or not with 50 ng/ml of TNF-α for 12 h. These supernatants, respectively, contain or not, the shedding HLA-G1 form. As previously described [40], 50 ng/ml of TNF-α gives a higher amount of HLA-G1 shedding form reaching 115 ng/ml.
As shown in Fig. 2, we described a significant degradation of IкB-α in column 5 corresponding to a co-incubation of NKL cells with culture supernatant of M8-HLA-G1 cells containing HLA-G1 shedding (p < 0.005 vs. column 4 corresponding to co-incubated NKL cells with culture supernatant of M8-HLA-G1 cells without HLA-G1 shedding molecule and p < 0.05 vs. column 1 corresponding to NKL cells alone control). We also described an IкB-α degradation when we co-incubate NKL cells with culture supernatant of M8-pcDNA cells without HLA-G1 shedding form. This later degradation, statistically not significant (Fig. 2), could be attributed to an induced cleavage due to the excess of TNF-α in the supernatant. Taken together, these data suggest that HLA-G1 soluble form is implicated in IкB-α degradation.
NF–кB pathway activation by HLA-G1 in NK cells does not implicate PI3K/Akt pathway
PI3K/Akt pathway is one of the ubiquitous signaling pathways leading to NF–кB activation [34]. In order to study the involvement of this pathway in NF–кB activation after HLA-G1 stimulation, cells were pre-incubated with 50 µM of LY-294.002, a specific inhibitor of PI3K for 1 h before incubation on a layer of M8-HLA-G1 cells for 15 and 30 min. The representative experiment shown in Fig. 3 demonstrates that there are no significant differences in IкB-α phosphorylation between treated and non-treated cells with the PI3K inhibitor in respective times. Statistical tests performed on densitometric measurements confirmed this observation. IкB-α phosphorylation was not blocked after inhibitor use, proving that NF–кB activation by HLA-G1 in NK cells does not implicate PI3K in this experimental condition.
To ascertain the obtained results, we studied the effect of a synthetic HLA-G peptide corresponding to the α1 domain (90 first amino acids of HLA-G exon 2). This later domain is, in one hand, shared by all HLA-G forms, and in the other hand, implicated in the inhibition of NK-cytolysis [29]. The performed experiments with the synthetic peptide gives the same result as presented in Fig. 3 (data not shown).
NF–кB pathway activation by HLA-G1 in NK cells does not implicate MAPK/ERK pathways
To determine whether NF–кB activation involves other pathways like MAPK/ERK pathway, we employed a specific inhibitor of MEK which is PD-98.059. Pre-treatment of NK cells with 30 µM of PD-98.059 for 1 h before incubation on a layer of M8-HLA-G1 cells for 15 and 30 min did not change the extent of IкB-α phosphorylation. This result suggests that MEK is not implicated in activation of NF–кB by HLA-G1 in NK cells (Fig. 4). We found the same results with the synthetic HLA-G peptide corresponding to the α1 domain (data not shown).
NF–кB pathway activation by HLA-G1 in NK cells is not implicated in cytotoxicity inhibition
To evaluate the implication of NF–кB activation by HLA-G1 molecule, we performed a cytotoxicity assay employing NKL cells as effectors cells and M8-pcDNA or M8-HLA-G1 as target cells. The assay confirmed the decrease in lysis capacity of NKL cells against M8-HLA-G1 both with untreated NKL cells and the DMSO-treated one. Moreover, NKL treatment with BAY 11-7082, a specific inhibitor of NF–кB pathway, has shown that NKL cell cytotoxicity inhibition by HLA-G1 is independent of NF–κB pathway. In fact, specific lysis percentage was not reversed after the use of M8-HLA-G1 cells (Fig. 5). Cytotoxicity assay analysis after NF–кB inhibition revealed also the same significant decrease with M8-pcDNA cells. These results obtained with NF–кB inhibitor demonstrated the implication of NF–кB pathway in NKL cytotoxicity.
Discussion
NK cells are known as potent immune cells implicated in innate responses as well as in adaptative responses after interaction, like with dendritic cells [6]. In the privileged cancer context, NK cells were largely represented [21, 35] as well as soluble HLA-G molecules [31, 32] suggesting a potential role of HLA-G molecules in NK cells signaling and probably in the modulation of their function. Membranous HLA-G1 molecules have been described as activators of NF–кB pathway toward NK cell lines [9]. However, the implication of soluble HLA-G forms in classical NF–кB pathway activation has not been investigated. To provide more insights into this activation, we used HLA-G5 and HLA-G1 shedding soluble molecules. Our choice was guided by the fact that, in one hand, HLA-G5 molecule, generated by alternative splicing, is the most described in cancer [31] and that, in the other hand, shedding HLA-G1 form, generated by proteolytic cleavage, is proposed to be enhanced in stress conditions associated to cancer [2].
In the current study, we reported for the first time that NK cell stimulation by soluble HLA-G5 activates NF–κB in a time-dependent manner (Fig. 1). The basal observed activation obtained with control beads could be explained by their composition and/or their elevated concentration of 4 × 103 beads/cell.
Moreover, we demonstrated an expressed IкB-α degradation, showing NF–кB activation upon stimulation by HLA-G1 shedding form (115 ng/ml; Fig. 2). In the same figure, we observed a significant decrease between control (column 1) compared with column 3 probably due to the excess of TNF-α needed for the cleavage of membranous HLA-G1 present in the surface of M8-HLA-G1 cells, contained in used culture medium. This observed decrease is enhanced after exposure to shedding HLA-G1 (column 3 vs. 5 in Fig. 2) showing that NF–кB activation, in NK cells, is dependent from shedding HLA-G1. These findings are in line with our previous study which has yielded that NF–кB was activated by membranous HLA-G1 form in NK cells after their co-culture with transfected melanoma cell line M8-HLA-G1 [9].
The demonstrated activation of NF–кB pathway either by soluble HLA-G5 or by shedding HLA-G1 form may occur probably through KIR2DL4 receptor. In fact, NF–кB activation was shown in YT2C2-PR cell line which expresses only KIR2DL4 receptor. However, we have not confirmed directly KIR2DL4's implication in NF–кB activation by soluble forms of HLA-G because of the absence of efficient blocker antibodies. But, we cannot exclude the implication of other unknown receptors for HLA-G in this activation.
Because it is well described that hypersignaling via the PI3K/AKT/mTOR axis might have an important role in cancer disease [38], and because PI3K and ERK are implicated in NK cytotoxicity function [10], we checked in this work the implication of PI3K and MEK in NF–кB activation. We demonstrated that pre-incubation of NK cells with specific inhibitors of PI3K and MEK do not change NF–кB level activation. We concluded that PI3K and MEK seem not to be implicated in this activation. But interestingly, another study has demonstrated the implication of Akt [34] and MAPK/ERK [37] in NF–кB activation. These disparities may be due to differences in model cells and/or working conditions.
The limitation of the present study is the absence of NK function's regulation dependent from NF–кB activation upon soluble HLA-G stimulation. In fact, the strong inhibitory effect of HLA-G molecule on NK cytotoxicity is completely independent of NF–кB (Fig. 5). This result was in agreement with Mami-Chouaib's study where NF–кB inhibition abrogates NK cytotoxicity [19]. Concerning immunomodulatory function, we hypothesize that the two forms of HLA-G, shedding HLA-G1 as well as soluble HLA-G5, might have the similar one. In fact, it was demonstrated that both proteins inhibit NK-mediated cytolysis [20, 22]. This could be explained by the same conformation shared by the two molecules. In fact, the unique structural difference founded between them is the cleaved amino acids (1 to 2 kDa) [22]. Further investigations will undoubtedly shed light on specific functions of HLA-G forms.
Because NK cells could secrete cytokines without degranulation [6], we proposed that activated NF–кB pathway by soluble HLA-G could be implicated in cytokine modulation and chemokine synthesis. The presence of NF–кB binding sites in numerous cytokine promoters, such as for IFN-γ, TNF-α, and IL-8 [7, 13, 33], and the results given by Rajagopalan study, which reported that soluble HLA-G protein can enhance pro-inflammatory and pro-angiogenic cytokines and also chemokines [25], underline this putative role of NF–кB activation. There is still a need to increase our knowledge about NF–кB activation after soluble HLA-G stimulation in such announced functions and also in other functions like apoptosis or inhibition of NK proliferation.
In summary, the present study corroborated our previous study showing that membranous HLA-G1 activates classical NF–κB pathway in NK cell [9]. Here, we have proved that HLA-G1 shedding form as well as soluble HLA-G5 form can activate NF–кB in NK cells. This activation is thought to be relevant in heterogeneous population of NK cells. We reported, elsewhere, that the activation of NF–кB does not require PI3K or MEK kinase function. Finally, further studies are needed to explore the role of NF–кB activation by soluble HLA-G forms in NK cells, giving new insights on HLA-G inhibitory function mechanism that might be exploited in future for therapeutic benefit.
References
Carosella E, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N (2003) HLA-G molecules: from maternal–fetal tolerance to tissue acceptance. Adv Immunol 81:199–252
Chang CC, Ferrone S (2003) HLA-G in melanoma: can the current controversies be solved? Semin Cancer Biol 13:361–369
Clements CS, Kjer-Nielsen L, Kostenko L, Hoare HL, Dunstone MA, Moses E, Freed K, Brooks AG, Rossjohn J, McCluskey J (2005) Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal–maternal interface. Proc Natl Acad Sci USA 102:3360–3365
Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, Lopez-Botet M (1997) A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 186:1809–1818
Davies C, Bem D, Young L, Eliopoulos A (2005) NF-kappaB overrides the apoptotic program of TNF receptor 1 but not CD40 in carcinoma cells. Cell Signal 17:729–738
El Kirwan S, Burshtyn D (2007) Regulation of natural killer cell activity. Curr Opin Immunol 19:46–54
Fujiie S, Hieshima K, Izawa D, Nakayama T, Fujisawa R, Ohyanagi H, Yoshie O (2001) Proinflammatory cytokines induce liver and activation-regulated chemokine/macrophage inflammatory protein-3 alpha/CCL20 in mucosal epithelial cells through NF-kappaB. Int Immunol 13:1255–1263
Gronning L, Cederberg A, Miura N, Enerback S, Tasken K (2002) Insulin and TNF alpha induce expression of forkhead transcription factor gene Foxc2 in 3T3-L1 adipocytes via PI3K and ERK 1/2-dependent pathways. Mol Endocrinol 16:873–883
Guillard C, Zidi I, Marcou C, Menier C, Carosella E, Moreau P (2008) Role of HLA-G in the innate immunity through the HLA-G mediated NF-kappaB activation in natural killer cells. Mol Immunol 45:419–427
Jiang K, Zhong B, Gilvary D, Corliss B, Hong-Geller E, Wei S, Djeu J (2000) Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol 1:419–425
Kanai T, Fujii T, Kozuma S, Yamashita T, Miki A, Kikuchi A, Taketani Y (2001) Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture. Mol Hum Reprod 7:195–200
Kanai T, Fujii T, Unno N, Yamashita T, Hyodo H, Miki A, Hamai Y, Kozuma S, Taketani Y (2001) Human leukocyte antigen-G-expressing cells differently modulate the release of cytokines from mononuclear cells present in the decidua versus peripheral blood. Am J Reprod Immunol 45:94–99
Karagiannides I, Kokkotou E, Tansky M, Tchkonia T, Giorgadze N, O'Brien M, Leeman S, Kirkland J, Pothoulakis C (2006) Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes. Proc Natl Acad Sci USA 103:5207–5212
Karin M, Greten FR (2005) NF–kappa B: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749–759
Le Gal F, Riteau B, Sedlik C, Khalil-Daher I, Menier C, Dausset J, Guillet J, Carosella E, Rouas-Freiss N (1999) HLA-G mediated-inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 11:101–106
Le Rond S, Azéma C, Krawice-Radanne I, Durrbach A, Guettier C, Carosella E, Rouas-Freiss N (2006) Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells. J Immunol 176:3266–3276
Le Rond S, Le Maoult J, Créput C, Menier C, Deschamps M, Le Friec G, Amiot L, Durrbach A, Dausset J, Carosella E, Rouas-Freiss N (2004) Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients. Eur J Immunol 34:649–660
Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED (2001) Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: A CD4+ T cell regulatory mechanism. Proc Natl Acad Sci USA 98:12150–12155
Mami-Chouaib F, Ameyar M, Dorothée G, Bentires-Alj M, Dziembowska M, Delhalle S, Gay F, Stancou R, Bours V, Chouaib S (2001) Effect of nuclear factor kappa B inhibition on tumor cell sensitivity to natural killer-mediated cytolytic function. Eur J Immunol 31:433–439
Marchal-Bras-Goncalves R, Rouas-Freiss N, Connan F, Choppin J, Dausset J, Carosella ED, Kirszenbaum M, Guillet J (2001) A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity. Transplant Proc 33:2355–2359
Papazahariadou M, Athanasiadis G, Papadopoulos E, Symeonidou I, Hatzistilianou M, Castellani M, Bhattacharya K, Shanmugham L, Conti P, Frydas S (2007) Involvement of NK cells against tumors and parasites. Int J Biol Markers 22:144–153
Park GM, Lee S, Park B, Kim E, Shin J, Cho K, Ahn K (2004) Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun 313:606–611
Paul P, Rouas-Freiss N, Moreau P, Cabestre F, Menier C, Khalil-Daher I, Pangault C, Onno M, Fauchet R, Martinez-Laso J, Morales P, Villena A, Giacomini P, Natali P, Frumento G, Ferrara G, McMaster M, Fisher S, Schust D, Ferrone S, Dausset J, Geraghty D, Carosella E (2000) HLA-G, -E, -F preworkshop: tools and protocols for analysis of non classical class I genes transcription and protein expression. Hum Immunol 61:1177–1195
Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, Gerritsen ME (1997) Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272:21096–21103
Rajagopalan S, Bryceson YT, Kuppusamy SP, Geraghty DE, van der Meer A, Joosten I, Long EO (2006) Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol 4:e9
Rajagopalan S, Long EO (1999) A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 189:1093–1100
Riteau B, Rouas-Freiss N, Menier C, Paul P, Dausset J, Carosella ED (2001) HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol 166:5018–5026
Rouas-Freiss N, LeMaoult J, Moreau P, Dausset J, Carosella ED (2003) HLA-G in transplantation: a relevant molecule for inhibition of graft rejection? Am J Transplant 3:11–16
Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED (1997) The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci USA 94:5249–5254
Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED (2005) HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 65:10139–10144
Sebti Y, Le Friec G, Pangault C, Gros F, Drenou B, Guilloux V, Bernard M, Lamy T, Fauchet R, Amiot L (2003) Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol 64:1093–1101
Sebti Y, Le Maux A, Gros F, De Guibert S, Pangault C, Rouas-Freiss N, Bernard M, Amiot L (2007) Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Br J Haematol 138:202–212
Sica A, Dorman L, Viggiano V, Cippitelli M, Ghosh P, Rice N, Young H (1997) Interaction of NF–kappaB and NFAT with the interferon-gamma promoter. J Biol Chem 272:30412–30420
Sizemore N, Leung S, Stark G (1999) Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF–kappaB p65/RelA subunit. Mol Cell Biol 19:4798–4805
Stagg J, Smyth M (2007) NK cell-based cancer immunotherapy. Drug News Perspect 20:155–163
Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U (2001) Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 92:369–376
Vanden BW, Plaisance S, Boone E, De Bosscher K, Schmitz M, Fiers W, Haegeman G (1998) p38 and extracellular signal-regulated kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 273:3285–3290
Xie C, Patel R, Wu T, Zhu J, Henry T, Bhaskarabhatla M, Samudrala R, Tus K, Gong Y, Zhou H, Wakeland E, Zhou X, Mohan C (2007) PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr. Int Immunol 19:509–522
Yan WH, Fan LA (2005) Residues Met76 and Gln79 in HLA-G alpha1 domain involve in KIR2DL4 recognition. Cell Res 15:176–182
Zidi I, Guillard C, Marcou C, Krawice-Radanne I, Sangrouber D, Rouas-Freiss N, Carosella E, Moreau P (2006) Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF–kB inducers. Cell Mol Life Sci 63:2669–2681
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zidi, I., Guillard, C., Carosella, E.D. et al. Soluble HLA-G induces NF–кB activation in natural killer cells. J Physiol Biochem 66, 39–46 (2010). https://doi.org/10.1007/s13105-010-0005-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13105-010-0005-y